腎上腺皮質癌市場 - 全球和區域分析：區域和國家分析 - 分析和預測（2025-2035）

全球腎上腺皮質癌 (ACC) 市場目前正處於其生命週期的成長階段。

儘管 ACC 仍然是一種罕見疾病和難以治療的癌症，但診斷技術和治療方案的進步預計將推動市場成長。此外，增加研究投入和臨床試驗也正在推動市場發展，加速新治療方法的開發。然而，由於發病率相對較低，導致患者數量有限且治療方法規模化採用緩慢，市場仍受到限制。儘管存在這些挑戰，但由於對個人化醫療的日益關注，市場預計仍將繼續成長。隨著更有針對性的治療方法和改進的治療通訊協定的推出，預計未來幾年市場將進一步成熟和擴大。

影響

• 預計在 2025-2035 年預測期內，對腎上腺皮質癌治療的需求不斷成長將支持全球腎上腺皮質癌市場的成長。
• 由於診斷技術的進步、創新治療方法的市場推出以及患者和醫療保健提供者意識的提高，全球腎上腺皮質癌市場預計將顯著成長。

近期動態

• 資金籌措2025 年 4 月，Cytovation 獲得 600 萬美元用於 CY-101 治療腎上腺皮質癌的臨床試驗。
• 夥伴關係2025 年 1 月，英國癌症研究中心、Cytovation 和挪威癌症協會簽署了一項協議，將 Cytovation 的主要資產 CY-101 推進到針對腎上腺皮質癌患者的跨國 2 期臨床試驗。

驅動程式

• 腎上腺皮質癌盛行率不斷上升
• 治療方案的持續進步
• 改進的診斷技術

限制因素

• 醫療費用高昂

產品/創新策略：全球腎上腺皮質癌市場的產品發布和創新專注於推進治療方案以改善患者護理。這些創新旨在提高治療效果並簡化疾病的檢測和管理。 Cytovation 等市場關鍵參與企業正在參與開發腎上腺皮質癌的治療方法。

競爭策略：主要關注全球腎上腺皮質癌市場領導的公司正在不斷致力於透過創新治療方法更新產品系列以保持競爭力。它對主要參與企業進行了詳細的競爭基準化分析，並提供了這些公司在產品供應、市場佔有率和創新方面的比較情況的見解。透過這種基準化分析，讀者可以清楚地了解市場格局和主要企業的地位。此外，包括夥伴關係、協議和聯盟在內的綜合競爭策略可協助讀者發現市場中尚未開發的商機。

本報告研究了全球腎上腺腺癌市場，並概述了市場以及區域趨勢和公司概況。

目錄

執行摘要

第1章全球腎上腺皮質癌市場概述

• 產業展望
  • 市場概況與生態系統
  • 市場趨勢
  • 腎上腺皮質癌流行病學分析
  • 臨床試驗
  • 監管狀況/合規性
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

2. 全球腎上腺皮質癌市場，按地區分類，百萬美元，2023-2035 年

• 北美洲
• 歐洲
• 亞太地區

3. 全球腎上腺皮質癌市場競爭基準化分析與公司概況

• 競爭格局
  • 各公司主要策略及發展
  • 關鍵進展
• 公司簡介
  • HRA Pharma
  • Cytovation
  • Exelixis, Inc.
  • Bristol-Myers Squibb

第4章調查方法

Market Lifecycle Stage

The global adrenocortical carcinoma market is currently in the growth stage of its lifecycle. While ACC remains a rare disease and challenging cancer to treat, advancements in diagnostic technologies and treatment options are expected to drive the growth of the market. The market is also benefiting from increased research investments and clinical trials, which are accelerating the development of new therapies. However, the market is still limited by the relatively low incidence of the disease, which restricts the patient pool and slows large-scale adoption of treatments. Despite these challenges, the growing focus on personalized medicine is expected to drive continued growth in the market. As more targeted therapies and improved treatment protocols are introduced, the market is poised for further maturation and expansion in the coming years.

Impact

• Increasing demand for adrenocortical carcinoma therapies is anticipated to support the growth of the global adrenocortical carcinoma market during the forecast period 2025-2035.
• The global adrenocortical carcinoma market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Recent Developments

• Fundings: In April 2025, Cytovation secured $6 million for the clinical trial of CY-101 aimed at treating adrenocortical carcinoma.
• Partnerships: In January 2025, Cancer Research UK, Cytovation, and the Norwegian Cancer Society signed an agreement to advance Cytovation's lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma.

Demand - Drivers and Limitations

Drivers:

• Increasing Prevalence of Adrenocortical carcinoma
• Continuous Advancements in Treatment Options
• Improved Diagnostic Technologies

Limitations:

• High Treatment Costs

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global adrenocortical carcinoma market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Cytovation, have been involved in the development of therapies for adrenocortical carcinoma.

Competitive Strategy: Enterprises led by market leaders in the global adrenocortical carcinoma market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• HRA Pharma
• Cytovation
• Exelixis, Inc.
• Bristol-Myers Squibb

Table of Contents

Executive Summary

Scope of Study

1. Global Adrenocortical Carcinoma Market Overview

• 1.1 Industry Outlook
  • 1.1.1 Market Overview and Ecosystem
  • 1.1.2 Market Trends
  • 1.1.3 Epidemiological Analysis of Adrenocortical Carcinoma
    • 1.1.3.1 By Region
  • 1.1.4 Clinical Trials
    • 1.1.4.1 By Phase
    • 1.1.4.2 By Sponsor Type
  • 1.1.5 Regulatory Landscape / Compliance
    • 1.1.5.1 Legal Requirement and Framework in the U.S.
    • 1.1.5.2 Legal Requirement and Framework in the E.U.
    • 1.1.5.3 Legal Requirement and Framework in Asia-Pacific
• 1.2 Market Dynamics
  • 1.2.1 Impact Analysis
  • 1.2.2 Market Drivers
  • 1.2.3 Market Restraints
  • 1.2.4 Market Opportunities

2. Global Adrenocortical Carcinoma Market, By Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Size and Forecast
    • 2.1.2.1 North America Adrenocortical Carcinoma Market (by Country)
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Size and Forecast
    • 2.2.2.1 Europe Adrenocortical Carcinoma Market (by Country)
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Size and Forecast
    • 2.3.2.1 Asia-Pacific Adrenocortical Carcinoma Market (by Country)
      • 2.3.2.1.1 Japan

3. Global Adrenocortical Carcinoma Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations, and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 HRA Pharma
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 Cytovation
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 Exelixis, Inc.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View
  • 3.2.4 Bristol-Myers Squibb
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers/End Users
    • 3.2.4.4 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Adrenocortical Carcinoma Market, Market Overview
• Figure: Global Adrenocortical Carcinoma Market, Epidemiological Analysis, U.S.
• Figure: Global Adrenocortical Carcinoma Market Coverage
• Figure: Global Adrenocortical Carcinoma Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Adrenocortical Carcinoma Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table Global Adrenocortical Carcinoma Market, Regulatory Scenario
• Table Global Adrenocortical Carcinoma Market Dynamics, Impact Analysis